References
1) World Health Organization HO (2020) Coronavirus disease 2019
(COVID-19) situationreport Available
fromhttps://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports.
2) Lin L et al. (2020) Hypothesis for potential pathogenesis of
Sars-CoV-2 infection a review of immune changes in patients with viral
pneumonia. Emerg Microbes Infect 9(1):727– 732.
3). Carey IM et al. (2018) Risk of infection in type1 and type 2
diabetes compared with the general population: a matched cohort study.
Diabetes Care 41(3):513–521.
4). Geerlings SE, Hoepelman AI (1999) Immune dysfunction in patients
with diabetes mellitus (DM). FEMS Immunol Med Microbiol
26(3–4):259–265.
5). Yang YM et al (2017) Impact of comorbidity on fatality rate of
patients with Middle East respiratory syndrome. Sci Rep 7(1):11307.
6). Garbati MA et al (2016) A comparative study of clinical presentation
and risk factors for adverse outcome in patients hospitalised with acute
respiratory disease due to MERS coronavirus or other causes. PLoS One
11(11):e0165978.
7) Allard R et al. (2010) Diabetes and the severity of pandemic
influenza A (H1N1) infection. Diabetes Care 33(7):1491–1493.
8) Wu Z, McGoogan JM (2020) Characteristics of and important lessons
from the coronavirus disease 2019 (COVID-19) outbreak in China: summary
of a report of 72314 cases from the Chinese Center for Disease Control
and Prevention. JAMA. 323(13):1239.
9) Guo W et al (2020) Diabetes is a risk factor for the progression and
prognosis of COVID-19. Diabetes Metab Res Rev e3319.
10) Yang JK et al (2006) Plasma glucose levels and diabetes are
independent predictors for mortality and morbidity in patients with
SARS.DiabetMed23(6):623–628.
11) Yang JK et al. (2009) Bindingof SARS coronavirus to its receptor
damages islets and causes acute diabetes. Acta Diabetol 47(3):193–199.
12)
RalphDeFronzo
et al. (2016) Metformin-associated lactic acidosis: Current perspectives
on causes and risk
Metabolism
Volume
65, Issue 2, February 2016, Pages 20-29
13) Liu, J et al.
(2017).
”Incretin
based treatments and mortality in patients with type 2 diabetes:
systematic review and meta-analysis”. BMJ (Clinical Research Ed.). 357:
j2499.
14)
McIntosh,
C et al. (2005). ”Dipeptidyl peptidase IV inhibitors: How do they work
as new antidiabetic agents?”. Regulatory Peptides. 128 (2): 159–65.
15) Bonora BM et
al. (2020).
”Extraglycemic
Effects of SGLT2 Inhibitors: A Review of the Evidence”.
Diabetes,
Metabolic Syndrome and Obesity: Targets and Therapy. 13: 161–174.
16)
Hemmingsen
B (2014).
”Sulfonylurea
versus metformin monotherapy in patients with type 2 diabetes: a
Cochrane systematic review and meta-analysis of randomized clinical
trials and trial sequential analysis”. CMAJ Open. 2 (3): E162–75.
17) Fang L et al. (2020) Are patients with Hypertension and diabetes
mellitus at increase drisk forC OVID-19 infection? Lancet Respir Med
8(4):e21.
18) Vaduganathan M et al. (2020) Renin–angiotensin–aldosterone system
inhibitors in patients with Covid-19. N Engl J Med 382(17):1653– 1659.
19) Patel AB, Verma A (2020) COVID-19 and angiotensin-converting enzyme
inhibitors and angiotensin receptor blockers: what is the evidence? JAMA
(3): E162–75.
20) Driggin E et al. (2020) Cardiovascular considerationsfor patients,
health care workers, andhealth systems during the coronavirus disease
2019 (COVID-19) pandemic. J Am Coll Cardiol.
https://doi.org/10.1016/j.jacc.2020.03.031 63.
21) Li Y, Wang M et al. (2020) Acute cerebrovascular disease following
COVID-19: a single center, retrospective, observational study. SSRN.
https://doi.org/10.2139/ssrn.3550025 64.
22) Bangash MN et al. (2020) COVID-19 and the liver: little cause for
concern. Lancet Gastroenterol Hepatol 11(1):2.
23) Zumla A et al. (2020) Reducing mortality from 2019-nCoV:
host-directed therapies should be an option. Lancet 395(10224):e35–e36.
24) Zumla A et al. (2016) Coronaviruses - drug discovery and therapeutic
options. Nat Rev Drug Discov 2016; 15: 327–47.
25) Raj VS et al (2013) Dipeptidyl peptidase 4 is a functional receptor
for the emerging human coronavirus-EMC. Nature 495(7440):251–256.
26) Iacobellis G (2020) COVID-19 and diabetes: can DPP4 inhibition
playarole?DiabetesResClinPract162:108125.
27) Feng Y et al (2020) Effect of hCMSCs and liraglutide combination in
ALI through cAMP/PKAc/β-catenin signaling pathway. Stem Cell Res Ther
11(1):2.